Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report

Advances in Therapy

Volumn 34, Issue 3, 2017, Pages 587-598

  Rey, Enrique ^a,b   Mearin, Fermín ^c   Alcedo, Javier ^d   Ciriza, Constanza ^e   Delgado Aros, Silvia ^f   Freitas, Teresa ^g   Mascarenhas, Miguel ^h   Mínguez, Miguel ⁱ   Santos, Javier ^j,k,l   Serra, Jordi ^l,m  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c CENTRO MÉDICO TEKNON   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f Neuro Enteric Translational Science (NETS) Research Group   (Spain)

^g CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

^h Hospital CUF Porto   (Portugal)

ⁱ UNIVERSITY OF VALENCIA   (Spain)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^m HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

Abdominal pain; Bloating; Constipation; Constipation predominant irritable bowel syndrome; Gastroenterology; Linaclotide; Patient management; Recommendations

Indexed keywords

LINACLOTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ATRIAL NATRIURETIC FACTOR RECEPTOR; GASTROINTESTINAL AGENT; NATRIURETIC PEPTIDE RECEPTOR C; PEPTIDE;

AGED; CLINICAL PRACTICE; CONSTIPATION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INTERACTION; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HUMAN; IRRITABLE COLON; KIDNEY FAILURE; LIVER FAILURE; NONHUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; PREGNANCY; REFRACTORY PERIOD; REVIEW; AGONISTS; IRRITABLE BOWEL SYNDROME; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

CONSTIPATION; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; PEPTIDES; RECEPTORS, ATRIAL NATRIURETIC FACTOR; TREATMENT OUTCOME;

EID: 85009237715     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-016-0473-8     Document Type: Review

References (32)

1. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393–407.
2. Rey E, Talley NJ. Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Dig Liver Dis. 2009;41(11):772–80.
3. Palsson OS, van Tilburg MA, Simren M, Sperber AD, Whitehead WE. Population prevalence of Rome IV and Rome III Irritable Bowel Syndrome (IBS) in the United States (US), Canada and the United Kingdom (UK). Gastroenterology. 2016;150(4):S739–40.
4. Rey E, Balboa A, Mearin F. Chronic constipation, irritable bowel syndrome with constipation and constipation with pain/discomfort: similarities and differences. Am J Gastroenterol. 2014;109(6):876–84.
5. Zomorrodi S, Rasoulzadeh Tabatabaie SK, Azadfallah P, Ebrahimidaryani N, Arbabi M. Long term effects of mindfulness on quality of life in irritable bowel syndrome. Iran J Psychiatry. 2015;10(2):100–5.
6. Boeckxstaens G, Camilleri M, Sifrim D, et al. Fundamentals of neurogastroenterology: physiology/motility—sensation. Gastroenterology. 2016;150:1292–304.
7. Rey Díaz-Rubio E, Mascort Roca JJ, Peña Forcada E, Cañones Garzón P, Tenias Burillo JM, Júdez Gutiérrez FJ. Management of the clinical issue of constipation with abdominal complaints in adults. A national survey of Primary Care physicians and gastroenterologists. Rev Esp Enferm Dig. 2016;108(6):323–31.
8. Mearin F, Ciriza C, Mínguez M, et al. Clinical Practice Guideline: irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108(6):332–63.
9. Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther. 2011;130(1):71–82.
10. Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol. 2010;649(1–3):328–35.
11. Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil. 2010;22(3):312-e84.
12. Brierley SM. Guanylate cyclase-C receptor activation: unexpected biology. Curr Opin Pharmacol. 2012;12(6):632–40.
13. Castro J, Harrington AM, Hughes PA, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′,5′-monophosphate. Gastroenterology. 2013;145(6):1334–46. e1–11.
14. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107(11):1714–24 (quiz p. 1725).
15. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702–12.
16. Quigley EM, Tack J, Chey WD, et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C—a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther. 2013;37(1):49–61.
17. Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(9):1084–1092.e3 (quiz e68).
18. Linaclotide data sheet. http://www.allergan.com/assets/pdf/linzess_pi. Accessed Oct 20, 2016.
19. CHMP summary of positive opinion for Constella. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002490/human_med_001597.jsp&mid=WC0b01ac058001d124. Accessed Oct 20, 2016.
20. ® (lin-ZESS) (linaclotide) capsules. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202811s000lbl.pdf. Accessed Oct 20, 2016.
21. Constella: EPAR—product information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002490/WC500135622.pdf. Accessed Oct 20, 2016.
22. NICE Guidelines: Irritable bowel syndrome with constipation in adults: linaclotide. https://www.nice.org.uk/advice/esnm16/chapter/Relevance-to-NICE-guidance-programmes. Accessed Oct 20, 2016.
23. Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139(6):1877–86.e2.
24. Busby RW, Kessler MM, Bartolini WP, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013;344(1):196–206.
25. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133(3):761–8.
26. Chey W, Shiff S, Schneier H, Hao X, Lavins B, Chickering J. Two years on linaclotide: tolerability and treatment satisfaction in IBS-C patients with and without diarrhea. Am J Gastroenterol. 2014;109(2):P1111.
27. Lacy BE, Schey R, Shiff SJ, et al. Linaclotide in chronic idiopathic constipation patients with moderate to severe abdominal bloating: a randomized, controlled trial. PLoS One. 2015;10(7):e0134349.
28. El-Serag HB, Pilgrim P, Schoenfeld P. Systemic review: natural history of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;19(8):861–70.
29. Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol. 2005;100(5):1174–84.
30. Camilleri M, Heading RC, Thompson WG. Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16(8):1407–30.
31. Diaz C, Falques M, Moya M, et al. Treatment satisfaction after retreatment and long-term therapy with linaclotide. United Eur Gastroenterol J. 2(1S):556. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212306/pdf/10.1177_2050640614548980.pdf. Accessed Oct 27, 2016.
32. A safety and efficacy study of a range of linaclotide doses administered orally to children ages 7–17 years, with irritable bowel syndrome with constipation (LIN-MD-63). https://clinicaltrials.gov/ct2/show/NCT02559817?term=linaclotide&rank=3. Accessed Oct 21, 2016.